Imatron bags CT orders worth $16 million
Ultrafast CT developerImatron of South San Francisco, CA, last week announced that itreceived an order for 10 C-150 scanners from Imatron Japan, aprivate corporation formed a year ago to handle sales and marketingof the scanners in Japan. The purchase
Ultrafast CT developerImatron of South San Francisco, CA, last week announced that itreceived an order for 10 C-150 scanners from Imatron Japan, aprivate corporation formed a year ago to handle sales and marketingof the scanners in Japan. The purchase will fill a significantorder of C-150 units Imatron Japan received from a large Japanesehospital group. Coupled with another order from Imatron Japanto refurbish three C-100 scanners, the total value of the agreementsis over $16 million, the company reported. The scanners will bedelivered in 1995 and 1996. Imatron Japan is controlled by a Japanesefirm, Tobu Land Systems, with Imatron and Kino Corp., anotherJapanese company, minority shareholders in the venture.
Strategies to Reduce Disparities in Interventional Radiology Care
March 19th 2025In order to help address the geographic, racial, and socioeconomic barriers that limit patient access to interventional radiology (IR) care, these authors recommend a variety of measures ranging from increased patient and physician awareness of IR to mobile IR clinics and improved understanding of social determinants of health.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Study: Monitoring of Prostate MRI Exams Could Lead to 75 Percent Reduction of Gadolinium Contrast
March 17th 2025While DCE MRI was deemed helpful in over 67 percent of cases in which it was used, researchers found that monitored prostate MRI exams, which facilitated a 75 percent reduction of DCE MRI sequences, had comparable sensitivity for prostate cancer as non-monitored exams.
